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Summary
Toll-like receptors (TLR) are transmembrane pattern recognition receptors that recognize 
microbial ligands and signal for production of inflammatory cytokines and type I interferon in 
macrophages and DC. Whereas TLR-induced inflammatory mediators are required for pathogen 
clearance, many are toxic to the host and can cause pathological inflammation when over-
produced. This is demonstrated by the role of TLR-induced cytokines in autoimmune diseases, 
such as rheumatoid arthritis, inflammatory bowel disease, and systemic lupus erythematosus. 
Because of the potent effects of TLR-induced cytokines, we have diverse mechanisms to dampen 
TLR signaling. Here, we highlight three pathways that participate in inhibition of TLR responses 
in macrophages and DC, and their implications in autoimmunity; A20, encoded by the TNFAIP3 
gene, Lyp encoded by the PTPN22 gene, and the BCAP/PI3K pathway. We present new findings 
that Lyp promotes TLR responses in primary human monocytes and that the autoimmunity risk 
Lyp620W variant is more effective at promoting TLR-induced IL-6 than the non-risk Lyp620R 
protein. This suggests that Lyp serves to downregulate a TLR inhibitory pathway in monocytes, 
and we propose that Lyp inhibits the TREM2/DAP12 inhibitory pathway. Overall, these pathways 
demonstrate distinct mechanisms of negative regulation of TLR responses, and all impact 
autoimmune disease pathogenesis and treatment.
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The principal function of the innate immune system is to recognize microbes and induce 
inflammatory responses that promote immediate pathogen control as well as initiate adaptive 
immunity. The innate immune system uses a diverse system of pattern recognition receptors 
(PRR) to survey both extracellular and intracellular niches to identify microbial pathogens 
and signal for appropriate inflammatory responses. Toll-like receptors (TLR) were the first 
defined class of PRR, and are found in evolutionarily diverse organisms, such as sponges, 
flies and mammals. The TLR family contains transmembrane receptors with share a 
common structure with leucine-rich repeats for ligand binding located extracellularly or in 
the endosome and a cytosolic signaling domain termed the Toll-IL-1 Receptor (TIR) 
domain.
TLR4 was the first mammalian TLR to have its specific ligand defined as the prototypical 
pathogen associated molecular pattern (PAMP) lipopolysaccharide (LPS), found in the cell 
wall of Gram negative bacteria(1). Since TLR4 was identified as the receptor for LPS, many 
microbe-specific TLR ligands have been found, including bacterial flagellin for TLR5, 
acylated lipoproteins for TLR2 heterodimers, and parasite profilin-like molecules for TLR10 
and TLR11. As microbe-specific TLR ligands were identified, it was easy to classify TLR as 
receptors that distinguish between self and non-self. But this distinction was quickly found 
to be incorrect, as TLR that reside in endocytic compartments recognize nucleic acids, 
which are common to microbes and the host(2). TLR9 recognizes double stranded DNA, 
TLR3 recognizes double stranded RNA, and TLR7 and TLR13 recognize single stranded 
RNA(3). All of these nucleic acid sensing receptors have the potential to recognize both 
foreign and self nucleic acids. These TLR presumably evolved to sense microbial nucleic 
acids and are therefore localized to endosomes to help protect against detection of self 
nucleic acids(4). We now know that some cell-surface localized TLR also have endogenous 
ligands (discussed below).
Signaling through TLR leads to a well-studied signaling cascade initiated by TIR domain-
containing signaling adapters, including MyD88, TRIF, TIRAP and TRAM, which interact 
with the TIR domain of the TLR(5,6). All TLR except TLR3 signal through MyD88, which 
leads to activation and nuclear translocation of NF-κB transcription factors, as well as 
MAPK pathway signaling leading to AP-1 activation, resulting in transcription of hundreds 
of pro-inflammatory genes (Fig. 1). These TLR-induced inflammatory genes include the 
prototypical pro-inflammatory cytokines TNF, IL-6 and IL-12 p40, as well as many 
chemokines that induce leukocyte homing to sites of infection to help begin the 
inflammatory process. In addition to induction of NF-κB-dependent inflammatory genes, 
many TLR also induce transcription of type I IFN genes that include the many genes 
encoding IFNα and the single IFNβ gene. TLR3 and TLR4 use TRIF, whereas TLR7 and 
TLR9 use MyD88, to induce activation and nuclear translocation of IRF3 and IRF7, 
resulting in IFNα and IFNβ gene transcription. Additionally, TLR7 and TLR9 use IRF5 to 
promote transcription of both inflammatory cytokines and type I interferon (IFN) (5). Thus 
TLR use several mechanisms to induce transcription of pro-inflammatory genes and type I 
IFN, both of which serve to alert the host to the presence of infection and promote immune 
activation and pathogen clearance.
Hamerman et al. Page 2









Pathological consequences of TLR signaling
Whereas TLR-induced inflammatory mediators are required for pathogen clearance, many 
of these molecules are toxic to the host and can cause pathological inflammation. This is 
most apparent with TNF, which has pleiotropic effects on many cell types and participates in 
the severe systemic inflammation seen in bacterially-induced sepsis, mainly through its 
effects on endothelial cells. Chronic TNF production is also found in target tissues of several 
autoimmune diseases where it promotes local inflammation(7). In Rheumatoid Arthritis 
(RA), TNF levels are elevated in affected joints and targeting this cytokine therapeutically is 
effective in many RA patients for alleviating joint inflammation. Elevated TNF is also seen 
in the intestinal tract of patients with inflammatory bowel disease (IBD) and TNF blockade 
is also effective in some IBD patients. IL-6, another prototypical TLR-induced inflammatory 
cytokine is also found in the joints of RA patients and monoclonal antibodies blocking IL-6 
are also effective in treatment of this disease(8). The effectiveness of IL-6 blockade in other 
autoimmune diseases is under investigation. Not only are TLR-induced NF-κB-dependent 
pro-inflammatory cytokines, such as TNF and IL-6, implicated in autoimmune disease, but 
the type I IFN cytokine family, induced by TLR signaling through IRF3 and IRF7 is also 
implicated in autoimmune diseases(9,10). In systemic lupus erythematosus (SLE), elevated 
type I IFN production and evidence for IFN signaling via the presence of a type I IFN 
signature is found in the blood and tissues of many patients. The amount of type I IFN or 
IFN signature in the blood of SLE patients correlates with disease activity, autoantibodies 
and clinical manifestations of disease(9,10). To date, therapies targeting type I IFN signaling 
have not proved effective for SLE, but there is some evidence that patients with a low IFN 
signature may benefit from these therapeutics(11).
It is clear that cytokines associated with TLR-induced responses to pathogens are also 
implicated in autoimmune diseases—they are abundant in target organs and cytokine or 
cytokine receptor blockade are some of the most effective therapeutics that have been 
developed for these diseases. Many of these cytokines can be induced by signaling pathways 
in addition to TLR. TNF and IL-6 are produced downstream of signaling from the IL-1R, 
which also signals via MyD88, as well as by TNF signaling itself, causing amplification of 
an initial TNF signal. Type I IFN are induced not only by TLR signaling, but also by 
signaling via cytoplasmic PRR, such as the RIG-I-like receptors, RIG-I and MDA5, and 
cGAS, after RNA and DNA recognition, respectively(4,12). This leads us to ask “what is the 
evidence for TLR involvement in autoimmune disease?”
The most direct link between TLR signaling and autoimmunity is seen in SLE, where 
pathogenic autoantibodies recognize autoantigens that contain TLR agonists, in this case 
ssRNA, the TLR7 ligand, or dsDNA, the TLR9 ligand(13). Autoantibodies in SLE may 
directly recognize TLR ligands or may recognize cellular proteins that bind nucleic acids, 
such as chromatin or snRNPs. In mouse models of SLE, genetic loss of TLR7 protects mice 
from disease, whereas the role of TLR9 is more complex and can either promote or 
exacerbate disease (reviewed in (14)). Conversely, overexpression of TLR7 in mice via a 
BAC transgene can recapitulate several aspects of SLE in the non-autoimmune prone B6 
mice and TLR7 overexpression due to a gene duplication of TLR7 causes disease in the 
BxSB SLE model(15,16). Genetic polymorphisms in the TLR7 locus have also been 
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implicated in SLE in people. The rs3853839 single nucleotide polymorphism (SNP) is 
located in the 3′UTR of the TLR7 gene and is associated with increased risk of SLE (G>C) 
and increased expression of TLR7 mRNA and protein(17–21). Additionally, inhibitors of 
TLR7 and TLR9 ameliorated lupus-like disease in a mouse models(22,23), and are being 
developed for use in SLE patients. Therefore, there is strong evidence that TLR, particularly 
TLR7, is involved in SLE pathogenesis, though in which cells, plasmacytoid DC, 
conventional DC or B cells, is less clear.
There is also evidence for a role of TLR in autoimmune diseases other than SLE. Many 
reports document increased TLR expression and increased TLR responses in peripheral 
blood mononuclear cells (PBMC) and/or monocytes from patients with a variety of 
autoimmune diseases, including type 1 diabetes, RA, and SLE. The increased TLR 
responses may be secondary to inflammation due to ongoing disease in these patients or be 
directly caused by genetic polymorphisms or epigenetic changes impacting TLR signaling. 
In RA, there is evidence for TLR signaling in amplifying inflammation in the joint both in 
synovial fibroblasts and macrophages (reviewed in(24,25)), and blocking or inhibiting 
TLR4, TLR8, TLR2, MyD88 or TIRAP in cultures of synovial membranes from RA 
patients reduces inflammatory cytokine production (reviewed in (26)). Assessing the role of 
TLR in mouse models of autoimmune disease requires using spontaneously occurring 
models as many induced diseases use adjuvants that require TLR signaling for their 
function. The common RA model collagen-induced arthritis (CIA) and common multiple 
sclerosis (MS) model experimental autoimmune encephalomyelitis (EAE) both use complete 
freund’s adjuvant to induce disease. In a spontaneous model of RA driven by IL-1R 
antagonist deficiency, TLR4-deficiency or blockade ameliorated disease(27–29). 
Surprisingly, TLR2 deficiency exacerbated disease due to effects on regulatory T cells in 
this model(27). Thus in RA, data from both human and mouse disease implicate TLR, but 
the identity and source of the TLR agonists is not clear. Some infections have been 
associated with RA and may be a source of TLR agonists, but endogenous TLR agonists 
from intestinal microbiota or from damaged tissues (discussed below) have also been 
implicated(24–26). Associations of TLR with RA, SLE and other autoimmune diseases 
suggest targeting these pathways may be efficacious, and inhibitors of TLR4 and nucleic 
acid sensing TLR are under clinical development.
Negative regulation of TLR signaling
Because of the potent effects of TLR-induced cytokines, we have evolved a variety of 
mechanisms to dampen the magnitude and duration of TLR signaling. These negative 
regulators of TLR signaling also help protect against aberrant activation of this signaling 
cascade by endogenous TLR ligands. In the case of nucleic acid sensing TLR, while 
localization to the endosomal system protects the innate immune system from responding to 
extracellular RNA and DNA released from necrotic cells, this does not protect from sensing 
nucleic acids from apoptotic cells that are phagocytosed into this very compartment. TLR4 
and TLR2/1 or TLR2/6 heterodimers signal not only in response to microbe-derived 
PAMPs, but also in response to endogenous ligands termed damage associated molecular 
patterns (DAMPs), some of which are released from dead and dying cells. These include 
HMGB1, a variety of heat shock proteins, fragments of extracellular matrix components 
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such as hyaluronic acid, oxidized phospholipids and oxidized LDL, among others. 
Microbiota found in the intestines, lung, skin and other epithelial surfaces are also a rich 
source of TLR agonists. Therefore, specialized mechanisms are also required to ensure 
inflammation is limited in response to low levels of DAMPs, to nucleic acids in apoptotic 
cells, and to TLR agonists derived from microbiota. A diverse array of proteins serve as 
negative regulators of TLR signaling to perform this critical function.
Negative regulators of TLR signaling have been found which intersect the TLR signaling 
pathway at almost every step. These negative regulators show diversity not only in how they 
inhibit TLR signaling, but also in expression. Some negative regulators are expressed 
ubiquitously, whereas several are specific to macrophages or epithelial cells. There is also 
diversity in the timing of expression. Expression of some negative regulators is induced by 
TLR signaling itself, and these inhibitors appear important in controlling the magnitude of 
the peak response as well as turning off the response. Other negative regulators are 
constitutively expressed and as such can influence the sensitivity of the initial response as 
well as the peak and duration of TLR signaling. Mice with deficiency in some constitutive 
inhibitors display spontaneous inflammatory or autoimmune diseases, suggesting they are 
important for controlling the basal inflammatory response to endogenous TLR ligands, 
whether host or microbiota-derived. The large number and diverse actions of TLR negative 
regulators underscores the toxicity of pro-inflammatory cytokines and type I IFNs, which 
when overproduced can lead to pathological consequences. The abundance and function of 
these inhibitors must be finely tuned to allow for a productive response to pathogens, while 
limiting responses to self.
When thinking about the many ways that TLR signaling can be inhibited, it is useful to 
break down the TLR recognition and signaling pathways into discrete steps that can be 
interfered with by host negative regulators (Fig. 1). Ligand binding—molecules that bind to 
PAMPs thereby blocking their binding to TLR or that degrade TLR ligands. Cytosolic signal 
transduction—proteins that interfere with any stage of signal transduction from TLR 
proximal TIR-domain adapters to activation of cytosolic transcription factors for 
translocation to the nucleus. This is by far the largest class of inhibitors that have been 
defined. Transcription of inflammatory mediators—interference with NF-κB, IRF3/7 or AP1 
DNA binding and/or activity in the nucleus. Sensing of the extracellular milieu—this class 
of inhibitors are cells surface receptors with endogenous ligands whose signaling can inhibit 
TLR responses. TLR co-engagement—receptors that are co-engaged with TLR or that sense 
the TLR ligand delivery method, such as in apoptotic cells, which inhibit or modify the TLR 
signal. As several reviews have covered TLR negative regulators in a broad manner (30,31), 
here, we will focus on three specific negative regulatory pathways that fall in several of 
these classes, and their implications for autoimmune disease.
A20—a deubiquitinase that inhibits TLR signaling and protects from 
autoimmunity
Proteins that directly inhibit the TLR signaling cascade are the largest group of identified 
TLR negative regulators(31). A20 is an example of a TLR negative regulator that fits within 
this class. A20 is a deubiquitinase with specificity for lysine 63 (K63)-linked ubiquitin 
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chains, a protein modification associated with signal transduction via recruitment of 
ubiquitin binding proteins, rather than proteasome-mediated degradation as is associated 
K48-linked ubiquitin chains (reviewed in(32,33)). After TLR crosslinking and subsequent 
recruitment and/or activation of MyD88, IRAK4 and then IRAK1/2 are recruited to the 
forming signaling node or “myddosome”. IRAK activation recruits TRAF6, a ubiquitin E3 
ligase, which mediates the addition of K63-linked ubiquitin chains to itself along with the 
E2 complex formed with Ubc13 and Uev1a proteins. This K63-linked polyubiquitylated 
TRAF6 can then bind TAB2 and TAB3, thereby recruiting TAK1 and mediating activation 
of the IKK complex and downstream NF-κB activation(5). A20 inhibits this process by 
cleaving K63-kinked ubiquitin chains from TRAF6, thereby impeding activation of this key 
point in TLR signal transduction(32,33). Interestingly, a large number of TLR negative 
regulators in addition to A20 also inhibit TRAF6 function, showing this is a critical node in 
TLR signal transduction(30,31).
The inhibitory function of A20 is supported by both human and mouse studies. Human 
genetic studies have identified many SNPs in and around the TNFAIP3 gene encoding A20 
associated with increased risk of autoimmune and inflammatory diseases. This broad list of 
diseases includes RA, SLE, psoriasis, Crohn’s disease, T1D, Sjogren’s syndrome, Systemic 
sclerosis and Juvenile idiopathic arthritis(32). Several TNFAIP3 polymorphisms associated 
with risk of autoimmunity that have been studied in detail cause reduced A20 function or 
expression, including the non-synonymous SNP rs2230926 (34) and a polymorphic 
dinucleotide in a putative 3′ enhancer (35), consistent with idea that A20 is an inhibitor of 
immune responses. Interestingly, reduced A20 expression has been documented in cells 
from patients with several autoimmune diseases, and reduced A20 expression and 
polymorphisms in TNFAIP3 have been associated with response to TNF blocking therapies 
in RA, psoriasis and Crohn’s disease(32,36).
What is the evidence that A20 inhibition of TLR signaling in myeloid cells is important in 
autoimmune disease? This is an important question because A20 is broadly expressed and 
can inhibit multiple signaling pathways. Though A20 has been documented to inhibit TLR 
signaling in both macrophages and DC, A20 also targets other pro-inflammatory signaling 
pathways in these cells, including Nod2 signaling by targeting RIP2 and TNFR1 signaling 
by targeting RIP1(32,33). A20 also inhibits IL-1R signaling as this receptor also signals 
through TRAF6. Additionally, A20 is broadly expressed in the immune system and in non-
hematopoietic cells, where it may promote autoimmune disease through targeting non-
myeloid cells. Evidence for the importance of A20 in inhibiting TLR responses in myeloid 
cells for prevention of autoimmunity comes from mouse models. A20 deficiency in all cells 
leads to a fatal inflammatory disease causing perinatal lethality that does not depend upon 
the presence of B or T cells, highlighting the potency of A20 as an inhibitor of inflammation 
in the non-lymphoid compartment(37). Conditional deletion using a floxed allele of Tnfaip3 
in macrophages and neutrophils with the Lysm-Cre strain caused the development of a 
spontaneous polyarticular arthritis similar to RA(38). This disease depended upon both 
MyD88 and TLR4 and could be ameliorated by treatment with blocking antibodies to IL-6, 
but not TNF. Thus, inhibition of TLR signaling in macrophages and neutrophils by A20 is 
important in protection from RA.
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Conditional deletion of A20 in DC with the CD11c-Cre strain also caused spontaneous 
autoimmune disease, with one group finding lupus-like disease and arthritis and another 
group finding IBD-like colitis with associated arthritis(39,40). Both of these strains showed 
highly activated DC that spontaneously produced inflammatory cytokines and which were 
hyper-responsive to TLR agonists. By crossing these mice with Myd88-deficient mice, one 
group found that the increased TLR-induced IL-6 secretion in A20-deficient DC was 
MyD88 dependent, but that the increased DC activation was MyD88-independent(38). Thus, 
the increased DC activation may be not be due to augmented TLR signaling or may be TLR-
dependent, but depend upon TRIF rather than MyD88. Together, these three mouse models 
with macrophage/neutrophil-specific A20 deletion and DC-specific A20 deletion clearly 
show that the ability of A20 to inhibit TLR responses in these myeloid cell populations is 
important in protection from autoimmune disease.
A20 is the prototype for a TLR negative regulator with strong associations with autoimmune 
disease. Not only are SNPs in A20 associated with a variety of autoimmune diseases, but 
mouse models of A20 deficiency have been informative in teasing apart the relative 
contributions of A20 in different hematopoietic lineages. A20 also highlights the common 
promiscuity among TLR negative regulators—A20 inhibits not only TLR signaling, but also 
several other signaling pathways that promote inflammatory responses. Therefore, dissecting 
the relative contribution of each pathway in mouse models is important. Several important 
questions have yet to be addressed about the role of A20 in autoimmunity. While A20 
deficiency has been a useful tool in the mouse, mouse strains that model more precisely the 
major autoimmunity risk variants of TNFAIP3 in a ubiquitous and cell type specific manner 
will allow for a better understanding of how these risk variants promote disease. Future 
studies will also more precisely define the function of myeloid cells from subjects carrying 
the autoimmunity risk alleles of TNFAIP3.
TLR regulation by Lyp and the autoimmunity associated Lyp620W variant
One of the strongest genetic associations for increased risk of autoimmunity after the HLA 
region is a SNP in the PTPN22 gene(41). The PTPN22-1858T allele is associated with 
increased risk of developing many autoimmune diseases, particularly those associated with 
pathogenic autoantibodies, including type 1 diabetes, rheumatoid arthritis, systemic lupus 
erythematosus, and Graves disease, among others(41). The association of the 
PTPN22-1858T allele with so many diverse autoimmune diseases suggests that it may have 
a broad role in promoting immune responses(42), similar to variants in TNFAIP3 discussed 
above. This idea is supported by several studies showing that subjects with the 
PTPN22-1858T allele are protected from pulmonary tuberculosis(43–45) and from severe 
bacterial infections post allogeneic hematopoietic stem cell transplantation(46), though this 
association with increased bacterial clearance was not seen in all studies of tuberculosis (47) 
or other infections (48–50). Thus, the PTPN22-1858T allele is associated not only with 
many autoimmune diseases, but may also be associated with increased protection from 
bacterial infection, particularly infection with Mycobacterium tuberculosis.
PTPN22 encodes lymphocyte tyrosine phosphatase (Lyp). As its name suggests, Lyp is a 
protein tyrosine phosphatase expressed in B and T cells and has been primarily studied in 
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these cell types. The normal function of Lyp has been most extensively studied in T cells, 
through knockdown, overexpression, and knockout models. Together, data from these 
systems show the normal function of Lyp and its mouse ortholog PEP in T cells is to 
negatively regulate T cell receptor (TCR) signaling through its interactions with kinases that 
participate in transducing TCR signals, including Lck, Fyn, and Zap-70 (reviewed in 
(51,52)). Lyp has also been reported to interact with a variety of important signaling 
molecules that may regulate its phosphatase function, such as Csk, and, conversely, Lyp 
may impact the function of its binding partners. In contrast, there is little evidence from 
PEP-deficient mice for a B cell-intrinsic role of Pep in regulating B cell receptor (BCR) 
signaling in an analogous manner(53). Though PEP-deficient mice have increased numbers 
of spontaneous germinal centers, this is thought to be because of T cell hyper-
responsiveness, not intrinsic defects in the B cells(51,53). However, in humans Lyp is 
thought to influence B cell development and survival. Increased Lyp expression is present in 
chronic lymphoid leukemia (CLL) and is thought to contribute to the escape of these cells 
from BCR-mediated death. In human cell lines Lyp inhibits BCR signaling via Syk and 
PLCγ, but also enhances AKT activity by preventing the activation of the CD22/SHIP 
regulatory circuit(54). Therefore, from mouse models of PEP deficiency and knockdown 
studies, Lyp/Pep primarily functions as a negative regulator of TCR signaling, however, 
human overexpression studies indicate that Lyp also impacts BCR signaling(54).
The autoimmunity risk allele PTPN22-1858T encodes a tryptophan at amino acid 620 
(Lyp620W), whereas the non-risk 1858C allele encodes an arginine at this position 
(Lyp620R)(41). Since the first association of the PTPN22-1858T allele with autoimmunity, 
the function of the Lyp620W variant has been under intensive investigation in both mouse 
and human systems, including in mouse strains engineered to express either the human 
Lyp-620W variant or the analogous mouse PEP-619W variant. While there have been some 
discordant findings in the field, studies performed in mice expressing the PEP619W 
demonstrate TCR and BCR hyper-responsiveness and subsequent alterations in T and B cell 
repertoire and selection consistent with a loss of function(55,56), and this has also been 
supported by studies in human cell lines(57). In human primary T and B cells the 
autoimmunity risk Lyp-620W variant demonstrates altered function with blunted TCR and 
BCR responses compared to the Lyp-620R protein, and additional alterations in signaling 
downstream of the antigen receptor that impact cell fate and survival ((58,59), reviewed in 
(51)). Interestingly, both human and mouse studies show the function of the Lyp-620W 
variant in promoting autoimmunity is not only important in T cells, but also in B 
cells(55,58). Thus, the role of Lyp and the Lyp620W variant in T and B cells is complex, 
and Lyp620W likely has unique functions compared to Lyp620R.
Lyp is also expressed in myeloid cells, such as monocytes, macrophages, DC, and 
neutrophils (60), and therefore the ability of the Lyp620W variant to promote autoimmunity 
may also have a contribution from these cell types that can both initiate and amplify immune 
responses. In parallel to the function of A20, possibly Lyp is an inhibitor of TLR responses 
due to dephosphorylation of a key tyrosine required for TLR signaling, this function is 
reduced by the Lyp620R variant, resulting in increased TLR responses. Alternatively, Lyp 
may serve to dephosphorylate an inhibitor of TLR signaling, thereby promoting TLR 
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responses, and Lyp620W may be more effective at turning off this inhibitory pathway. 
Lastly, the non-risk variant of Lyp, Lyp620R, may have no role in regulating TLR 
responses, but the Lyp620W variant may have a novel target that regulates TLR signaling. 
Several recent studies, including our own described below, help shed light on the function of 
Lyp and Lyp620W on TLR signaling in myeloid cells.
Several groups have recently compared the function of the Lyp620R and Lyp620W proteins 
in regulating TLR responses in myeloid cells, predominantly in mouse models. Zhang et al. 
generated knockin mice that expressed the mouse ortholog of the Lyp620W variant, 
Lyp619W, and found that bone marrow-derived DC from these mice displayed increased 
LPS-induced activation as measured by CD40 upregulation, IL-12 secretion and ability to 
induce antigen-specific T cell proliferation, compared to wild-type mice expressing the 
Lyp619R protein(56). In the spleen, Lyp619W mice had increased DC numbers and 
increased CD40 expression constitutively. Though these authors assessed the responses of 
human primary B and T cells from subjects with the PTPN22-1858C and PTPN22-1858T 
alleles, they did not assess whether DC from these subjects also showed DC hyper-
responsiveness(56). Additionally, Zhang et al. propose that the Lyp620W variant is a 
hypomorph due to increased calpain-mediated degradation, suggesting that Lyp is a negative 
regulator of DC TLR responses in the mouse. Subsequent work has challenged the notion 
that the Lyp620W protein has reduced stability and expression compared to the Lyp620R 
protein(55,61), implying that the increased DC TLR responses in the Lyp619W mice is due 
to a lack of a specific TLR inhibitory function of Lyp in these cells rather than a lack of 
expression of Lyp.
Subsequently, Wang et al. examined macrophage and DC TLR responses in both Ptpn22−/− 
mice and in a model of expression of Lyp620R or Lyp620W under the control of the 
endogenous promoter elements from a human BAC transgene expressed in Ptpn22−/− 
mice(61). They found that macrophages and DC from Ptpn22−/− mice produced less TLR-
induced type I IFN than from WT mice. This was true downstream for TLR3 and TLR4 
signaling in bone marrow-derived macrophages and DC, and for TLR7 and TLR9 signaling 
in bone marrow-derived plasmacytoid DC (pDC), and this defect in type I IFN production 
was shown both in vitro and in vivo. In contrast to the defect in TLR-induced type I IFN 
production, Wang et al. found no change in TLR-induced inflammatory cytokine 
production, including TNF, IL-6 and IL-12 p40 production(61). From these and other 
experiments using Ptpn22−/− mice, the authors concluded that Lyp is a positive regulator of 
TLR-induced type I IFN production and has no effect on TLR-induced inflammatory 
cytokine production.
Wang et al. next investigated the ability of the human Lyp620R and Lyp620W transgenes to 
rescue type I IFN production in Ptpn22−/− bone marrow-derived DC and macrophages and 
found that whereas the expression of the non-risk Lyp620R protein greatly increased LPS-
induced IFNβ production, expression of the risk variant Lyp620W had little effect(61). 
Lastly the authors examined PBMC and PBMC-derived DC from healthy PTPN22-1858C/C 
homozygotes and PTPN22-1858C/T heterozygotes. The authors found lower IFN-stimulated 
gene (ISG) induction, but no change in TNF, IL6 or IL8 induction, in PTPN22-1858C/T 
heterozygotes compared to 1858C/C homozygotes, consistent with their findings in mice. 
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Mechanistically, Wang et al. showed that Lyp promotes TLR-induced type I IFN through 
interactions with TRAF3 resulting in increased TRAF3 K63-ubiquitinylation and that 
Lyp620W does not have this function (61). More recently, this group followed up their 
findings in primary human plasmacytoid DC from patients with SLE comparing those 
homozygous for the PTPN22-1858C allele to those carrying one or two copies of the 
PTPN22-1858T allele(62). In this study, the authors found that pDCs carrying the 
PTPN22-1858T allele produced less TLR7-induced IFNα than PTPN22-1858C/C 
homozygotes. Together, these studies led the authors to conclude that Lyp620R is a positive 
regulator of TLR-induced type I IFN production and that Lyp620W is defective in this 
function. This work revealed an interesting new function for Lyp and showed that Lyp620W 
is a loss-of-function variant in TLR-induced type I IFN production in macrophages and DC. 
However, it is difficult to reconcile this lack of TLR-induced type I IFN production, 
particularly from pDC, with the increased susceptibility of carriers of the PTPN22-1858C 
allele to SLE where TLR-induced type I IFN is thought to promote disease.
We also investigated the role of Lyp in TLR signaling. Our interest stemmed from our 
previous work showing that signaling from the immunoreceptor TREM2 and its signaling 
chain DAP12 inhibit TLR responses in mouse macrophages and DC in an immunoreceptor 
tyrosine-based activation motif (ITAM)-dependent manner requiring the Syk and Btk/Tec 
tyrosine kinases(63–66). As Lyp inhibits TCR signaling and the Lyp620W protein affects 
both BCR and TCR signaling, which occur via ITAM-mediated signals similar to those 
transduced by TREM2/DAP12, we posited that Lyp might also inhibit TREM2/DAP12 
signaling. As TREM2/DAP12 signaling inhibits TLR responses, this inhibition of an 
inhibitory pathway would allow Lyp to serve as a positive regulator of TLR responses.
First, we examined whether inhibition of Lyp phosphatase function in monocytes affected 
TLR responses. For these experiments, we purified CD14+ monocytes from PBMC of 
healthy subjects using magnetic bead enrichment, rested the cells for 2 hours, treated with 
either of two Lyp inhibitors (I-C11 or 8b) or vehicle control, and then activated with LPS 
and measured TNF and IL-6 secretion after overnight culture(67,68). We performed a 
careful dose response of LPS on monocytes from several donors to ensure we were using a 
non-saturating dose, because, from our experience, high doses of TLR agonists can mask 
regulatory pathways. Both Lyp inhibitors significantly reduced LPS-induced secretion of 
IL-6 and TNF in monocytes (Fig. 2A and B). Interestingly, Lyp inhibition had a greater 
effect on IL-6 secretion than on TNF secretion with the I-C11 inhibitor (IL-6, 36.5 +/− 3.4% 
inhibition; TNF, 15.9 +/− 4.2% inhibition), though we did not see this same effect with the 
8b inhibitor (IL-6, 12.6 +/− 2.8% inhibition; TNF, 11.6 +/− 2.4% inhibition) that may be 
explained by the 5-fold lower concentration of 8b used compared to I-C11. These data show 
that in primary human monocytes, Lyp phosphatase activity promotes TLR-induced 
inflammatory cytokines. These data lend support to a model where Lyp turns off an 
inhibitory pathway, thereby serving as a positive regulator.
We next investigate the role of the Lyp620W variant in controlling TLR responses in 
monocytes. We purified CD14+ monocytes from PBMC from healthy subjects with no first-
degree relatives with autoimmunity bearing the PTPN22-1858C/C or PTPN22-1858C/T 
genotype and treated with non-saturating doses of LPS, CpG DNA or PAM3CSK4. 
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Monocytes from PTPN22-1858C/T subjects produced significantly more IL-6 than 
monocytes from PTPN22-1858C/C subjects in response to both LPS and CpG-A (Fig. 3A 
and B). This difference was less pronounced at higher doses, where it did not reach 
statistical significance (Fig. 3C and D). Interestingly, we saw only a small increase in CpG-
induced TNF secretion from PTPN22-1858C/T subjects, and no difference in LPS-induced 
TNF secretion between groups (Fig. 3A–D). This is consistent with the stronger effect of the 
I-C11 Lyp inhibitor on IL-6 secretion than TNF secretion (Fig. 2A). We saw similar trends 
with TLR2/1 responses to PAM3CSK4, though we had few subjects after excluding TLR1 
genotypes that result in TLR2/1 unresponsiveness(69) (J. Pottle and J.A. Hamerman, 
unpublished observations). We then asked if healthy subjects with the PTPN22-1858C/T 
genotype had increased systemic signs of innate immune activation compared to 
PTPN22-1858C/C subjects by examining serum cytokine levels. Interestingly, we found a 
significant increase in serum IL-8 in subjects heterozygous for the PTPN22-1858C/T 
autoimmunity risk allele, consistent with increased basal inflammation in these otherwise 
healthy subjects, potentially through increased TLR responses (Fig. 4). Therefore, the 
expression of the Lyp620W variant associated with increased risk of many autoimmune 
diseases causes increased inflammatory responses in vitro and in vivo.
Our Lyp inhibitor data indicates that both Lyp620W and Lyp620R can function to promote 
TLR responses in monocytes, as we saw reduced LPS-induced cytokines after inhibitor 
treatment in both PTPN22-1858C/C and PTPN22-1858C/T subjects (J.Pottle and J.A. 
Hamerman, unpublished observations). Furthermore, the fact that PTPN22-1858C/T 
subjects secrete more LPS and CpG DNA-induced IL-6 compared to PTPN22-1858C/C 
subjects demonstrates that the Lyp620W variant associated with enhanced risk of 
autoimmunity has an increased ability to promote TLR responses in comparison with the 
Lyp620R protein. These data suggest Lyp may dephosphorylate and thereby turn off a 
negative regulator of TLR signaling in monocytes. The Lyp620W variant may have 
increased activity against this TLR negative regulator compared to Lyp620R. Alternatively, 
Lyp620W may dephosphorylate a unique inhibitor of TLR signaling that is not 
dephosphorylated by Lyp620R, consistent with the evidence discussed above that the 
Lyp620W variant has altered phosphatase function in lymphocytes compared to Lyp620R.
While there are many potential substrates through which Lyp may promote TLR responses 
in monocytes by turning off an inhibitory pathway, many of which are likely yet to be 
identified, we favor a model in which Lyp dephosphorylates Syk or the DAP12 ITAM 
tyrosines. In T cells, Lyp dephosphorylates the Syk family kinase Zap-70 and the CD3 
ITAM tyrosines in T cells(51). Syk has also been identified as a Lyp target(70). This would 
lead to reduced ITAM-mediated inhibition of TLR responses, which depend upon ITAM 
tyrosine phosphorylation and Syk(63), and higher TLR-induced cytokine secretion when 
Lyp activity is increased, and conversely increased ITAM-mediated inhibition of TLR 
responses and lower TLR-induced cytokine secretion when Lyp activity is reduced (Fig. 5). 
Alternatively, Lyp and Lyp620W may act upon other TLR inhibitory molecule or molecules 
yet to be identified.
Our data support the findings of Zhang et al. discussed above in which expression of the 
mouse variant analogous to Lyp620W (Lyp619R) causes increased DC TLR inflammatory 
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responses in comparison with the wild-type Lyp allele(56). Zhang et al. did not assess 
monocyte or macrophage TLR-induced inflammatory cytokines, but we would predict they 
would also see increased responses as these are similarly regulated as DC IL-12 secretion. 
Our data are distinct from those of Wang et al., who show no difference in TLR-induced 
inflammatory cytokine production using bone marrow-derived DC from wild-type and 
Ptpn22−/− mice, DC from Ptpn22−/− mice with BAC transgenes expressing the Lyp620W 
and Lyp620R proteins, and PBMC-derived DC from PTPN22-1858C/C subjects(61). This 
could be due to differences between the monocytes used in our studies and the DC used by 
Wang et al., but we find it more likely that the difference is due to the high dose of TLR 
agonists used in their study—100 ng/ml LPS for mouse cells and 1 μg/ml LPS for human 
cells—that may overcome the Lyp-mediated regulation of inflammatory cytokine 
production. We did not measure IFNβ or IFNα mRNA or protein expression in our 
experiments, but it is interesting to note that there is often a reciprocal effect of regulators on 
NF-κB-dependent production of inflammatory cytokines, such as TNF, IL-6 and IL-12, and 
IRF3/7-dependent production of type I IFN. Therefore, decreased type I IFN production is 
often accompanied by increased inflammatory cytokines.
In conclusion, our work in human monocytes along with the work of Zhang et al. in mouse 
DC, suggest a novel function for Lyp in promoting TLR responses. As expression of the 
Lyp620W variant encoded by the PTPN22-1858T allele is associated with risk of many 
autoimmune diseases, this suggests that Lyp may have a broad role in promoting immune 
responses, not only in lymphocytes, but also in myeloid cells. The association of Lyp620W 
with increased TLR responses may lead to an increased inflammatory state with every 
infection, and in response to endogenous host-derived or microbiota-derived TLR ligands, in 
subjects carrying the PTPN22-1858T allele, thereby cooperating with dysregulated T and B 
cell responses and promoting autoimmunity. Our findings suggest that Lyp inhibitors may 
be efficacious in blunting inflammation in autoimmunity through their effects on myeloid 
cells.
Further investigation of the role of Lyp in TLR responses is needed as at the moment there 
are more questions than answers. These include: 1) What is(are) the target(s) of Lyp620R 
and Lyp620W required for inhibition of TLR-induced inflammatory cytokines in monocytes? 
We propose Lyp dephosphorylates the DAP12 ITAM tyrosines, Syk or other downstream 
mediators of the TREM2/DAP12 inhibitory pathway, but Lyp may have a variety of targets 
that influence TLR signaling. 2) What is the relationship between Lyp inhibition of TLR-
induced type I IFN and Lyp promotion of TLR-induced inflammatory cytokines? It is 
intriguing that Lyp both inhibits TLR-induced type I IFN and promotes TLR-induced 
inflammatory cytokines, suggesting Lyp may alter the balance of activation between the NF-
κB and IRF3/7 pathways, potentially by regulating the trafficking of TLR. 3) Does 
Lyp620W function in macrophages or DC promote autoimmunity? Myeloid-specific 
expression of the Lyp620W protein in mouse models are critical to dissect the cell-intrinsic 
contribution of the variant in autoimmune disease. 4) Does Lyp regulate signaling pathways 
in addition to TLR responses in monocytes? Interestingly, two recent papers suggest that 
Lyp regulates IFNγR signaling in macrophages(71,72), and Lyp may regulate other 
important pathways in these cells such as Fc receptor signaling, TNF signaling and IL-1R 
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signaling. TREM2/DAP12 signaling can inhibit not only TLR signaling, but also FcR 
signaling in macrophage(64). 5) What is the role of Lyp in neutrophils? Neutrophil 
responses are important in some autoimmune diseases, particularly in RA and SLE. In 
neutrophils, one study implicated Lyp620W in increased protein citrullination and increased 
NETosis, whereas another study implicated this risk variant in increased neutrophil adhesion 
and reactive oxygen species (ROS) production(73,74).
TLR inhibition by PI3-kinase signaling
In addition to the activation of the NF-κB, IRF3/7 and MAPK pathways, TLR ligation also 
leads to activation of the lipid kinase phosphatidylinositol 3-kinase (PI3K) and its 
downstream signaling mediators. Whereas the NF-κB and MAPK pathways are pro-
inflammatory, many studies have found that class I PI3K signaling serves to negatively 
regulate TLR signaling in macrophages and dendritic cells. Class IA PI3K consists of a 
catalytic subunit (p110α, β, or δ) and a regulatory subunit, the most abundant of which is 
p85α. The catalytic p110 subunit and regulatory p85 subunit are constitutively found in the 
cytoplasm in an inactive PI3K complex(75). The p85α subunit contains two SH2 domains 
that bind with high affinity to phosphotyrosines within YxxM sequences found in a variety 
of proteins. The SH2-dependent binding to p-YxxM within proteins causes a conformational 
change in the p85 subunit, resulting in increased catalytic activity of the associated p110 
protein, and recruitment of the PI3K complex to the plasma membrane where it can access 
its substrate PI(4,5)P2 resulting in PI(3,4,5)P3 production(76). This causes the recruitment 
and activation of PDK-1 and Akt and subsequent activation of the downstream signaling 
cascade. Thus, binding of p85 to phosphorylated-YxxM sequences is critical for initiating 
PI3K signaling.
There is abundant evidence in the literature that PI3K pathway activation limits TLR 
signaling in macrophages and DC. This is seen using pharmacological inhibitors of the PI3K 
pathway in human monocytes and macrophages(77–79) as well as in studies with 
macrophages or dendritic cells from mice modified genetically to have altered PI3K. This 
was first seen with mice lacking the p85α regulatory subunit, which displayed increased 
TLR-induced DC production of IL-12, which allowed Balb/c mice typically susceptible to 
Leishmania major infection to clear this pathogen due to enhanced IL-12 dependent Th1 
responses(80). This has been extended with mice deficient in proteins activated by the PI3K 
pathway, including the key downstream kinases PDK-1(81) and Akt1(82,83) as well as 
pharmacological inhibition of Akt(78). Conversely, macrophages lacking PTEN, the 
phosphatase that counters PI3K activity by catalyzing the removal of the phosphate added 
by PI3K, have reduced TLR-induced cytokine production, and mice with macrophage-
specific PTEN deficiency had delayed clearance of Leishmania major(84–86). Thus, the 
PI3K pathway is a potent negative regulator of downstream of TLR signaling.
Several pathways have been implicated downstream of PI3K in inhibition of TLR responses 
in macrophages and DC, including induction of IL-10 via mTOR, activation of GSK3β, and 
phosphorylation and nuclear export of Foxo1(87–91). IL-10 is a potent anti-inflammatory 
cytokine produced by macrophages and DC in response to TLR agonists that signals through 
STAT3 to inhibit inflammatory responses, and dysregulated IL-10 production has been 
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implicated in inflammatory diseases. Several studies have shown that PI3K pathway 
mediated activation of the mTOR complex promoted IL-10 secretion in response to LPS, 
and identified the mTORC2 complex that includes Rictor as specifically regulated by 
PI3K(88,90,92). Therefore, one mechanism by which PI3K activation inhibits inflammatory 
responses is via mTORC2 induction of IL-10 secretion, which then feeds back on 
macrophages by activating STAT3. Two groups also showed that there are IL-10 
independent mechanisms by which PI3K inhibits TLR-induced TNF, IL-6 and IL-12 
production that depend upon activation of GSK3β(88,93). Lastly, Foxo1, a member of the 
forkhead family of transcription factors whose activity is regulated by the PI3K pathway, 
has been implicated downstream of TLR-induced PI3K signaling in macrophages. In the 
absence of PI3K activation, Foxo1 is found in the nucleus bound to Foxo1 consensus DNA 
sequences. After activation of the PI3K pathway, active Akt, phsophorylated by PDK1 and 
mTORC2, can phosphorylate Foxo1 on three amino acids (Thr24/Ser256/Ser319) resulting 
in the export of Foxo1 from the nucleus into the cytoplasm, causing the termination of 
Foxo1-dependent transcription(94). Nuclear export of Foxo1 has been implicated in 
terminating transcription of several genes downstream of LPS-induced PI3K, Akt1 and 
mTORC2 activation in macrophages, including expression of IL-12 p40, IL-6 and IL-1β(89–
91). Therefore, there are likely several different mechansims by which PI3K pathway 
activation inhibits TLR-induced inflammatory responses.
The studies described above show a clear inhibitory function of the PI3K pathway on TLR 
responses, but the exact mechanism by which PI3K is activated downstream of TLR ligation 
was not clear. Several studies showed that TLR2, TLR3 and TLR5, and TIRAP and MyD88, 
can directly bind the p85 subunit of PI3K after tyrosine phosphorylation in over-expression 
studies, many of which were performed in non-hematopoietic cells(95–99). Additionally, all 
TLR can activate the PI3K pathway, suggesting there may be additional mechanisms for 
PI3K activation. As binding of the p85 PI3K subunit to phosphorylated YxxM sequences is 
a general mechanism for activating class I PI3K, we hypothesized there is a myeloid-
expressed YxxM protein linking TLR ligation to PI3K activation. One candidate was B cell 
adapter for PI3K (BCAP), a protein first identified in B cells(100), but with broad 
expression in hematopoietic cells including B cells, NK cells, neutrophils, monocytes, 
macrophages, and DC. BCAP is a large cytosolic protein with four YxxM motifs that are 
tyrosine phosphorylated after BCR crosslinking and subsequently recruit and activate the 
p85/p110 complex and downstream signals(100,101). BCAP also participates in PI3K 
activation in NK cells(102). Because of the high expression of BCAP in macrophages, we 
investigated if BCAP links TLR signaling to activation of the PI3K pathway and therefore 
serves as an inhibitor of TLR responses(103).
The first clue that BCAP was the elusive YxxM-containing adapter between TLR and PI3K 
activation came from an examination of TLR-induced cytokine production in BCAP-
deficient (Pik3ap1−/−) mice. We found increased TNF, IL-6 and IL-12 p40 secretion in 
response to TLR4, TLR7 and TLR9 agonists in Pik3ap1−/− macrophages compared to wild-
type macrophages, and increased serum IL-12 p40 after LPS injection in Pik3ap1−/− mice 
compared to wild-type mice(103). Thus, BCAP is a negative regulator of TLR responses in 
mice, and macrophages lacking BCAP phenocopy deficiency in the PI3K p85 regulatory 
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subunit or macrophages treated with PI3K inhibitors. We next specifically examined the 
PI3K pathway activation by measuring phosphorylation of two sites on Akt required for its 
activation, Thr308, the site directly phosphorylated by PDK-1, and Ser473, a site 
phosphorylated by mTORC2(76). Pik3ap1−/− macrophages had reduced LPS-induced 
phosphorylation at both sites on Akt compared to wild-type macrophages, showing that as in 
B and NK cells, BCAP mediates activation of the PI3K pathway. This was specific to TLR 
signaling as TNF-mediated Akt phosphorylation was no different between wild-type and 
Pik3ap1−/− macrophages. Importantly, we showed that BCAP’s four YxxM tyrosines were 
required for the ability of BCAP to inhibit TLR responses in macrophages, proving that the 
mechanism by which BCAP inhibits TLR responses requires PI3K p85 binding. 
Interestingly, we found that BCAP was constitutively tyrosine phosphorylated and bound to 
p85 PI3K in macrophages and this phosphorylation did not change in response to LPS 
treatment, but instead BCAP was recruited to membranes after LPS signaling(103). 
Therefore, BCAP may function to bring the active p85/p110 complex to the membrane 
where it can access its substrate PI(4,5)P2, thereby generating PI(3,4,5)P3 that can recruit 
and activate PDK-1 initiating the PI3K signaling cascade.
Simultaneous to our work, two other groups identified this inhibitory role for BCAP in 
macrophages(104,105). Troutman et al. came to study BCAP in a unique manner, through a 
bioinformatics search for new TIR-containing proteins(104). They found that BCAP 
contains a TIR homology domain in its previously uncharacterized N-terminus, and can bind 
to both MyD88 and TIRAP through this interaction, though this was only shown in a 
transfection system in 293T cells. Importantly, Troutman et al. also demonstrated the anti-
inflammatory effects of BCAP in vivo using two models(104). They found an increase in 
TNF-producing monocytes in the spleen early after infection with Salmonella Typhimurium 
and an increase in severity of DSS-mediated colitis in Pik3ap1−/− mice. Though these in 
vivo studies are consistent with increased TLR responses in the absence of BCAP, many 
innate pathways in addition to TLR can contribute to inflammation in these models.
From these studies, we are left with a model in which BCAP is recruited to the forming 
myddosome, potentially by interactions with MyD88 and TIRAP. This may explain the 
membrane recruitment of BCAP we see shortly after LPS treatment(103). BCAP brings the 
p85/p110 complex to its lipid substrate in membranes, where it can catalyze the formation of 
PI(3,4,5)P3 that recruits and activates PDK1, thereby initiating the downstream activation of 
Akt and downstream pathways. There are several outstanding questions about how BCAP 
functions to activate TLR signaling. 1) What kinase(s) phosphorylate BCAP in 
macrophages? In B cells, Syk and Btk have been shown to participate in BCR-mediated 
BCAP phosphorylation and Lyn in CD19-mediated BCAP phosphorylation. c-Abl has also 
been shown to tyrosine phosphorylate BCAP in K562 human CML cell line(106). In 
macrophages, we found that Syk-deficient macrophages have increased, not decreased 
BCAP phosphorylation(103), ruling out Syk as the BCAP kinase. Future studies will 
examine other kinases, both those implicated in BCAP phosphorylation and related kinases. 
What is the role of BCAP in myeloid cells in vivo? Because of the broad expression of 
BCAP in hematopoietic cells, cell-type specific deletion of BCAP is critical to investigate its 
function in vivo, both in macrophages and conventional DC. BCAP is also highly expressed 
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in pDC and neutrophils and therefore may have important functions in these cells. What 
pathways in addition to TLR-induced PI3K can BCAP regulate? BCAP does not affect 
TNF-induced Akt phosphorylation(103,104), but BCAP likely inhibits IL-1R-induced PI3K 
activation and may also regulate other key signaling pathways in macrophages. Therefore, a 
comprehensive analysis of what pathways BCAP can regulate is warranted. What are the 
downstream pathways used by BCAP and PI3K to inhibit TLR-induced inflammatory 
responses? As discussed above, several pathways downstream of PI3K have been 
implicated in inhibiting TLR responses. We found no difference in IL-10 secretion between 
LPS-treated wild-type and BCAP-deficient macrophages, suggesting differences in IL-10 
are not responsible. Our preliminary analyses show that levels of LPS-induced 
phosphorylated Foxo1 (Ser256) in the nucleus are dramatically reduced in BCAP-deficient 
macrophages compared to wild-type macrophages (M. Ni and J.A. Hamerman, unpublished 
observations), suggesting that BCAP promotes Akt-mediated phosphorylation and nuclear 
export of Foxo1, thereby terminating Foxo1-dependent transcription. Future studies will 
further investigate if activation of Foxo1 is required for BCAP-mediated inhibition of TLR 
responses.
Lastly, we ask, What is the impact of BCAP and PI3K-mediated inhibition of TLR responses 
on autoimmune disease? No SNPs in the PIK3AP1 locus have been associated with 
autoimmune diseases, but this many not be surprising because loss of BCAP function may 
reduce B cell survival(101), in addition increasing inflammatory responses. Therefore, how 
BCAP functions in macrophages and DC in autoimmunity will require cell-type specific 
deletion mouse models. Particularly interesting will be to assess models associated with 
increased TLR signaling, including models of SLE, RA and IBD. We predict that specific 
deletion of BCAP in macrophages and/or DC will cause an increase in severity of these 
diseases. Interestingly, the impact of myeloid PI3K signaling has not been investigated 
thoroughly in mouse models of autoimmunity, though this could be done using an existing 
conditional allele of the phosphatase Pten crossed to either CD11c-Cre or LysM-Cre strains, 
which would have decreased TLR signaling in targeted cells due to increased PIP3 levels. 
One study used Lysm-Cre/Ptenfl/fl mice to determine the role of PI3K in two arthritis 
models. The authors found the Lysm-Cre/Ptenfl/fl mice were protected from collagen-
induced arthritis, but not from K/BxN serum transfer arthritis(107). Clearly, more studies of 
this kind are needed both using existing conditional PTEN mice with increased PI3K 
activity, as well as development of models with cell type specific and inducible reductions in 
PI3K activity.
Understanding the impact of macrophage and DC PI3K inhibition is a relevant question for 
autoimmunity because pan or selective class I PI3K inhibitors are being tested in clinical 
trials or are in pre-clinical development for treatment of autoimmune diseases, such as RA 
and psoriasis, inflammatory diseases such as asthma and COPD, and various forms of 
cancer(108–110). Some of these inhibitors have shown efficacy in mouse models of 
autoimmune disease, particularly models of SLE and RA, but a p110δ inhibitor has been 
tested in a phase 2 clinical trial in RA, but did not have efficacy(108). While these inhibitors 
are being developed and used based upon the idea that PI3K signaling promotes immune 
responses in B and T cells or promotes survival and growth of malignant cells, the impact of 
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these inhibitors on the anti-inflammatory functions of PI3K in macrophages and DC needs 
to be considered. This is particularly important because of their likely long-term use if used 
in treatment of asthma and COPD, as well as in autoimmune diseases(111). Supporting this 
idea, mice with targeted inactivation of the catalytic PI3K subunit p110δ develop 
spontaneous colitis(112,113), and colitis, among other side effects, was caused by treatment 
of patients with a selective p110δ inhibitor for follicular B-cell non-Hodgkin lymphoma or 
relapsed small lymphocytic lymphoma(114,115). Therefore, a better understanding of the 
role of class I PI3K in both in innate and adaptive immune cells is warranted, including 
inhibitory roles of this pathway.
Concluding remarks
Here, we have highlighted only three of many pathways that have been shown to inhibit 
TLR responses in macrophages and DC, and have discussed implications of each of these 
pathways for autoimmune disease pathogenesis and treatment. There are TLR negative 
regulators that have been investigated in autoimmunity that we were not able to cover here, 
as well as many that have not yet been studied in the context of autoimmunity. Two proteins 
we discuss, A20 and Lyp, have risk variants broadly associated with autoimmunity, 
suggesting they have general roles in promoting immune responses, but by distinct 
mechanisms. In macrophages and DCs, A20 inhibits TLR signaling directly, whereas we 
propose that Lyp is involved in turning off inhibitory pathways through its phosphatase 
function, potentially through TREM2 and DAP12. No variants in genes encoding BCAP or 
the class I PI3K pathway have been associated with autoimmunity to date, however 
contrasting activating and inhibitory functions of these pathways in lymphocytes and 
myeloid cells may complicate this type of analysis. In fact, all three of the inhibitory 
pathways discussed here have in common broad expression amongst hematopoietic cells, 
regulation of multiple signaling pathways, and complex functions, making further study of 
each pathway in inhibiting TLR responses critical to better understanding both productive 
and pathogenic immune responses.
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Figure 1. Model of TLR signaling with select negative regulators
MyD88-dependent TLR signaling can be inhibited at any step along the signaling pathway. 
We have highlighted in red text select inhibitors that exemplify inhibition at different steps 
of the pathway. Those in a red box are discussed further in this review. For example, soluble 
forms of TLR2 and TLR4 inhibit signaling by blocking ligand binding to the TLR. SOCS1, 
A20 and IRAK-M block key steps in signal transduction downstream of most TLR (A20 and 
IRAK-M) or TLR4 (SOCS1). ATF3 is a transcription factor that dampens the transcription 
of inflammatory genes by recruiting histone deacetylases to the promoters of pro-
inflammatory genes. BCAP is a signaling adapter that inhibits TLR signaling through PI3-
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kinase (PI3K) activation. One downstream mediator of PI3K inhibition of TLR responses is 
the transcription factor FOXO1, whose removal from the nucleus helps terminate 
transcription of some pro-inflammatory genes. The TREM2/DAP12 receptor signals in 
response to endogenous glycoproteins and lipids, thereby sensing the extracellular milieu of 
the macrophage. Signaling through TREM2/DAP12 inhibits TLR responses through 
reducing MAPK (Erk1/2) activation. Here we propose this pathway is regulated by the 
tyrosine phosphatase Lyp.
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Figure 2. Inhibition of Lyp decreases TLR responses in monocytes
CD14+ monocytes were isolated from freshly thawed PBMC and rested for 2 hours before 
addition of A) Lyp inhibitor I-C11 (5 μM) or B) 8b (1 μM) or DMSO control. After 30 
minutes monocytes were treated with 0.1 ng/ml LPS (S. minnesota R595, List Biological 
Laboratories, Campbell, CA, USA) and supernatants were collected after 16 hours. TNF and 
IL-6 were measured by ELISA (eBioscience, San Diego, CA, USA). These inhibitors did 
not cause cytotoxicity during the overnight culture as measured by LDH release assay (J. 
Pottle and J.A. Hamerman, unpublished observations). Statistical significance was 
determined using a paired Wilcoxon matched pairs signed rank test.
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Figure 3. Monocytes from PTPN22C/T subjects have increased TLR4 and TLR9-induced 
cytokine production
CD14+ monocytes were isolated from freshly thawed PBMC and rested for 2 hours before 
addition of CpG-A (Invivogen, San Diego, CA, USA) or LPS (S. minnesota R595, List 
Biological Laboratories). Supernatants were collected after 16 hours and TNF and IL-6 
measured by ELISA. Doses were as follows: A) Low dose CpG-A 1 μM, B) Low dose LPS 
0.025 ng/ml, C) High dose CpG-A 5 μM, D) High dose LPS 0.1 ng/ml. Statistical 
significance was determined using the Mann-Whitney test. Healthy subjects were recruited 
through the Benaroya Research Institute immune-mediated disease registry. The research 
protocols were approved by the institutional review board at the Benaroya Research 
Institute.
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Figure 4. Healthy subjects with PTPN22C/T genotype have higher serum IL-8 than PTPN22C/C 
subjects
Serum IL-8 was measured by Bio-plex assay (Bio-Rad, Hercules, CA, USA) in 20 subjects 
of each genotype. Statistical significance was determined using a Mann-Whitney test.
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Figure 5. Potential model for regulation of TLR signaling by Lyp downstream of the TREM2/
DAP12 inhibitory pathway
Signaling through TREM2/DAP12 inhibits TLR responses through the DAP12 ITAM 
tyrosines, Syk and Btk/Tec. A) We hypothesize that the Lyp620R variant has the capacity to 
dephosphorylate Syk and/or the DAP12 ITAM tyrosines, resulting in partial phosphorylation 
of the DAP12 ITAM and/or Syk. This causes a reduction in the function of the TREM2/
DAP12 inhibitory pathway in monocytes and macrophages, thereby moderating TLR-
induced NF-kB-dependent inflammatory cytokine production. B) We propose that when Lyp 
activity is inhibited, there is increased phosphorylation of DAP12 or increased signaling 
through Syk, resulting in a stronger inhibitory signal through TREM2/DAP12 and reduced 
IL-6 and TNF secretion. C) We propose that Lyp620W has a greater capacity to 
dephosphorylate DAP12 or Syk. This results in reduced DAP12 or Syk phosphorylation and 
a weaker inhibitory signal through TREM2/DAP12, leading to increased IL-6 and TNF 
secretion. Alternatively, Lyp620W may dephosphorylate a unique, distinct inhibitor than 
Lyp620R, thereby promoting TLR-induced IL-6 and TNF secretion.
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